Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:08 PM
Ignite Modification Date: 2025-12-24 @ 11:08 PM
NCT ID: NCT00150969
Eligibility Criteria: Inclusion Criteria: Postmenopausal: One year since the natural cessation of menses, or Hysterectomy with either postmenopausal status confirmed by FSH lab values, or age 55 and above AND 2. Osteopenic: T-score at baseline has to be between (and including) -1.0 and -2.0 in the lumbar spine (L1-L4), total hip or femoral neck, and the lowest reading of the above three measurements must be between -1.0 and -2.0 Exclusion Criteria: 1. Women ever having had a fragility fracture after age 40; 2. Women currently on anticoagulants, previously on anticoagulants in the past 3 months, or expected to be on anticoagulants in the near future; 3. Women on hormone replacement therapy, raloxifene, bisphosphonates or calcitonin during the past 3 months; 4. Women who have ever been on a bisphosphonate for more than 6 months; 5. Women previously diagnosed with Paget's disease, hyperparathyroidism, hyperthyroidism or other metabolic bone diseases; 6. Women with decompensated diseases of the liver, kidney, pancreas, lung, or heart; 7. Women with a history of active cancer in the past 5 years; 8. Women taking mega-doses of vitamin A (more than 10,000 iu per day) or E (more than 400 iu per day); 9. Women involved in other clinical trials; 10. Any women who, in the opinion of the principal investigator, is at poor medical or psychiatric risk for the study.
Healthy Volunteers: True
Sex: FEMALE
Minimum Age: 18 Years
Maximum Age: 100 Years
Study: NCT00150969
Study Brief:
Protocol Section: NCT00150969